31 publications
| Name | Date | Type | Actions |
|---|---|---|---|
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
Public releases | ||
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
Public releases | ||
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
Public releases | ||
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
Public releases | ||
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
Public releases | ||
CALENDAR 2023 Stock exchange market – non authorized periods The "negative windows" are the abstention periods during which it is forbidden to trade in the Company's securities. |
Financial Documents | ||
Q3 2011 Sales Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year. |
Public releases | ||
Jacques du Puy appointed Vétoquinol Managing Director Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment |
Public releases | ||
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
Public releases |